Implication of different effector mechanisms by cord blood-derived and peripheral blood-derived cytokine-induced killer cells to kill precursor B acute lymphoblastic leukemia cell lines

Cytotherapy

Volumn 16, Issue 6, 2014, Pages 845-856

  Durrieu, Ludovic ^a,b   Lemieux, William ^a,b   Dieng, Mame Massar ^a   Fontaine, François ^a   Duval, Michel ^a,b   Le Deist, Françoise ^a,b   Haddad, Elie ^a,b  

^a UNIVERSITY OF MONTREAL   (Canada)

^b UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

Cord blood; Cytokine induced killer cells; NKG2D; Peripheral blood; Precursor B acute lymphoblastic leukemia; TRAIL

Indexed keywords

CD56 ANTIGEN; FAS ANTIGEN; GRANULYSIN; GRANZYME B; HLA A ANTIGEN; HLA B ANTIGEN; HLA DR4 ANTIGEN; HLA DR5 ANTIGEN; NATURAL CYTOTOXICITY TRIGGERING RECEPTOR 1; NATURAL CYTOTOXICITY TRIGGERING RECEPTOR 2; NATURAL CYTOTOXICITY TRIGGERING RECEPTOR 3; NATURAL KILLER CELL RECEPTOR NKG2D; PERFORIN; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; KLRK1 PROTEIN, HUMAN; NATURAL KILLER CELL LECTIN LIKE RECEPTOR SUBFAMILY K; TNFSF10 PROTEIN, HUMAN;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANTIGEN EXPRESSION; APOPTOSIS; ARTICLE; BLOOD; CD3+ T LYMPHOCYTE; CELL DIFFERENTIATION; CONTROLLED STUDY; CYTOKINE INDUCED KILLER CELL; CYTOLYSIS; CYTOTOXICITY; EX VIVO STUDY; INTRACELLULAR SIGNALING; LEUKEMIA CELL LINE; MONONUCLEAR CELL; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; T LYMPHOCYTE SUBPOPULATION; UMBILICAL CORD BLOOD; UMBILICAL CORD BLOOD MONONUCLEAR CELL; BIOLOGICAL THERAPY; CELL LINE; CYTOLOGY; FETUS BLOOD; HUMAN; METABOLISM; PATHOLOGY; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PRECURSOR B-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; TRANSPLANTATION;

CELL LINE; CELL- AND TISSUE-BASED THERAPY; CYTOKINE-INDUCED KILLER CELLS; CYTOTOXICITY, IMMUNOLOGIC; FETAL BLOOD; HUMANS; NK CELL LECTIN-LIKE RECEPTOR SUBFAMILY K; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PRECURSOR B-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; TNF-RELATED APOPTOSIS-INDUCING LIGAND;

EID: 84899706173     PISSN: 14653249     EISSN: 14772566     Source Type: Journal    
DOI: 10.1016/j.jcyt.2013.12.010     Document Type: Article

References (39)

1. Schmidt-Wolf I.G., Negrin R.S., Kiem H.P., Blume K.G., Weissman I.L. Use of a SCID mouse/human lymphoma model to evaluate cytokine-induced killer cells with potent antitumor cell activity. J Exp Med 1991, 174:139-149.
2. Schmidt-Wolf I.G., Lefterova P., Mehta B.A., Fernandez L.P., Huhn D., Blume K.G., et al. Phenotypic characterization and identification of effector cells involved in tumor cell recognition of cytokine-induced killer cells. Exp Hematol 1993, 21:1673-1679.
3. Introna M., Franceschetti M., Ciocca A., Borleri G., Conti E., Golay J., et al. Rapid and massive expansion of cord blood-derived cytokine-induced killer cells: an innovative proposal for the treatment of leukemia relapse after cord blood transplantation. Bone Marrow Transplant 2006, 38:621-627.
4. Lu P.H., Negrin R.S. A novel population of expanded human CD3+CD56+ cells derived from T cells with potent in vivo antitumor activity in mice with severe combined immunodeficiency. J Immunol 1994, 153:1687-1696.
5. Verneris M.R., Ito M., Baker J., Arshi A., Negrin R.S., Shizuru J.A. Engineering hematopoietic grafts: purified allogeneic hematopoietic stem cells plus expanded CD8+ NK-T cells in the treatment of lymphoma. Biol Blood Marrow Transplant 2001, 7:532-542.
6. Edinger M., Cao Y.A., Verneris M.R., Bachmann M.H., Contag C.H., Negrin R.S. Revealing lymphoma growth and the efficacy of immune cell therapies using in vivo bioluminescence imaging. Blood 2003, 101:640-648.
7. Sweeney T.J., Mailander V., Tucker A.A., Olomu A.B., Zhang W., Cao Y., et al. Visualizing the kinetics of tumor-cell clearance in living animals. Proc Natl Acad Sci U S A 1999, 96:12044-12049.
8. Wongkajornsilp A., Somchitprasert T., Butraporn R., Wamanuttajinda V., Kasetsinsombat K., Huabprasert S., et al. Human cytokine-induced killer cells specifically infiltrated and retarded the growth of the inoculated human cholangiocarcinoma cells in SCID mice. Cancer Invest 2009, 27:140-148.
9. Kim H.M., Lim J., Park S.K., Kang J.S., Lee K., Lee C.W., et al. Antitumor activity of cytokine-induced killer cells against human lung cancer. Int Immunopharmacol 2007, 7:1802-1807.
10. Kim H.M., Lim J., Yoon Y.D., Ahn J.M., Kang J.S., Lee K., et al. Anti-tumor activity of ex vivo expanded cytokine-induced killer cells against human hepatocellular carcinoma. Int Immunopharmacol 2007, 7:1793-1801.
11. Kim Y.J., Lim J., Kang J.S., Kim H.M., Lee H.K., Ryu H.S., et al. Adoptive immunotherapy of human gastric cancer with ex vivo expanded T cells. Arch Pharm Res 2010, 33:1789-1795.
12. Petvises S., Pakakasama S., Wongkajornsilp A., Sirireung S., Panthangkool W., Hongeng S. Ex vivo generation of cytokine-induced killer cells (CD3+ CD56+) from post-stem cell transplant pediatric patients against autologous-Epstein-Barr virus-transformed lymphoblastoid cell lines. Pediatr Transplant 2007, 11:511-517.
13. Durrieu L., Gregoire-Gauthier J., Dieng M.M., Fontaine F., le Deist F., Haddad E. Human interferon-alpha increases the cytotoxic effect of CD56(+)cord blood-derived cytokine-induced killer cells on human B-acute lymphoblastic leukemia cell lines. Cytotherapy 2012, 14:1245-1257.
14. Sangiolo D., Martinuzzi E., Todorovic M., Vitaggio K., Vallario A., Jordaney N., et al. Alloreactivity and anti-tumor activity segregate within two distinct subsets of cytokine-induced killer (CIK) cells: implications for their infusion across major HLA barriers. Int Immunol 2008, 20:841-848.
15. Verneris M.R., Karami M., Baker J., Jayaswal A., Negrin R.S. Role of NKG2D signaling in the cytotoxicity of activated and expanded CD8+ T cells. Blood 2004, 103:3065-3072.
16. Hayakawa Y., Smyth M.J. NKG2D and cytotoxic effector function in tumor immune surveillance. Semin Immunol 2006, 18:176-185.
17. Bauer S., Groh V., Wu J., Steinle A., Phillips J.H., Lanier L.L., et al. Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA. Science 1999, 285:727-729.
18. Franceschetti M., Pievani A., Borleri G., Vago L., Fleischhauer K., Golay J., et al. Cytokine-induced killer cells are terminally differentiated activated CD8 cytotoxic T-EMRA lymphocytes. Exp Hematol 2009, 37:616-628 e2.
19. Pievani A., Borleri G., Pende D., Moretta L., Rambaldi A., Golay J., et al. Dual-functional capability of CD3+CD56+ CIK cells, a T-cell subset that acquires NK function and retains TCR-mediated specific cytotoxicity. Blood 2011, 118:3301-3310.
20. Kuci S., Rettinger E., Voss B., Weber G., Stais M., Kreyenberg H., et al. Efficient lysis of rhabdomyosarcoma cells by cytokine-induced killer cells: implications for adoptive immunotherapy after allogeneic stem cell transplantation. Haematologica 2010, 95:1579-1586.
21. Falschlehner C., Schaefer U., Walczak H. Following TRAIL's path in the immune system. Immunology 2009, 127:145-154.
22. Linn Y.C., Lau L.C., Hui K.M. Generation of cytokine-induced killer cells from leukaemic samples with in vitro cytotoxicity against autologous and allogeneic leukaemic blasts. Br J Haematol 2002, 116:78-86.
23. Marin V., Dander E., Biagi E., Introna M., Fazio G., Biondi A., et al. Characterization of in vitro migratory properties of anti-CD19 chimeric receptor-redirected CIK cells for their potential use in B-ALL immunotherapy. Exp Hematol 2006, 34:1219-1229.
24. Di Pietro R., Secchiero P., Rana R., Gibellini D., Visani G., Bemis K., et al. Ionizing radiation sensitizes erythroleukemic cells but not normal erythroblasts to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated cytotoxicity by selective up-regulation of TRAIL-R1. Blood 2001, 97:2596-2603.
25. Qiu G., Jiang J., Liu X.S. Pentamidine sensitizes chronic myelogenous leukemia K562 cells to TRAIL-induced apoptosis. Leuk Res 2012, 36:1417-1421.
26. Li Y., Schmidt-Wolf I.G., Wu Y.F., Huang S.L., Wei J., Fang J., et al. Optimized protocols for generation of cord blood-derived cytokine-induced killer/natural killer cells. Anticancer Res 2010, 30:3493-3499.
27. Zhang H., Cui Y., Voong N., Sabatino M., Stroncek D.F., Morisot S., et al. Activating signals dominate inhibitory signals in CD137L/IL-15 activated natural killer cells. J Immunother 2011, 34:187-195.
28. Lin S.J., Yan D.C., Lee Y.C., Hsiao H.S., Lee P.T., Liang Y.W., et al. Umbilical cord blood immunology: relevance to stem cell transplantation. Clin Rev Allergy Immunol 2012, 42:45-57.
29. Dolstra H., Fredrix H., Maas F., Coulie P.G., Brasseur F., Mensink E., et al. A human minor histocompatibility antigen specific for B cell acute lymphoblastic leukemia. J Exp Med 1999, 189:301-308.
30. Reid G.S., Bharya S., Klingemann H.G., Schultz K.R. Differential killing of pre-B acute lymphoblastic leukaemia cells by activated NK cells and the NK-92 ci cell line. Clin Exp Immunol 2002, 129:265-271.
31. Cosman D., Mullberg J., Sutherland C.L., Chin W., Armitage R., Fanslow W., et al. ULBPs, novel MHC class I-related molecules, bind to CMV glycoprotein UL16 and stimulate NK cytotoxicity through the NKG2D receptor. Immunity 2001, 14:123-133.
32. Salih H.R., Antropius H., Gieseke F., Lutz S.Z., Kanz L., Rammensee H.G., et al. Functional expression and release of ligands for the activating immunoreceptor NKG2D in leukemia. Blood 2003, 102:1389-1396.
33. Groh V., Wu J., Yee C., Spies T. Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation. Nature 2002, 419:734-738.
34. Wajant H., Moosmayer D., Wuest T., Bartke T., Gerlach E., Schonherr U., et al. Differential activation of TRAIL-R1 and -2 by soluble and membrane TRAIL allows selective surface antigen-directed activation of TRAIL-R2 by a soluble TRAIL derivative. Oncogene 2001, 20:4101-4106.
35. Sheard M.A., Asgharzadeh S., Liu Y., Lin T.Y., Wu H.W., Ji L., et al. Membrane-bound TRAIL supplements natural killer cell cytotoxicity against neuroblastoma cells. J Immunother 2013, 36:319-329.
36. Niu Q., Wang W., Li Y., Qin S., Wang Y., Wan G., et al. Cord blood-derived cytokine-induced killer cells biotherapy combined with second-line chemotherapy in the treatment of advanced solid malignancies. Int Immunopharmacol 2011, 11:449-456.
37. Introna M., Pievani A., Borleri G., Capelli C., Algarotti A., Mico C., et al. Feasibility and safety of adoptive immunotherapy with CIK cells after cord blood transplantation. Biol Blood Marrow Transplant 2010, 16:1603-1607.
38. Laport G.G., Sheehan K., Baker J., Armstrong R., Wong R.M., Lowsky R., et al. Adoptive immunotherapy with cytokine-induced killer cells for patients with relapsed hematologic malignancies after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 2011, 17:1679-1687.
39. Linn Y.C., Niam M., Chu S., Choong A., Yong H.X., Heng K.K., et al. The anti-tumour activity of allogeneic cytokine-induced killer cells in patients who relapse after allogeneic transplant for haematological malignancies. Bone Marrow Transplant 2012, 47:957-966.